Interpreting cancer vaccine clinical trials.
A number of cancer vaccine strategies have entered initial Phase I clinical testing. In this review, Dr. Glenn Dranoff discusses the prospects that appropriate immunologic monitoring of patients in these trials can help delineate important differences among the various immunization strategies and prioritize the most promising approaches for further clinical development.
Dranoff
G
G
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. glenn-dranoff@dfci.harvard.edu
D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines